Carnosic acid, a compound found in the herb rosemary, can block the interaction with the COVID-19 SARS_CoV_2 spike protein and ACE2, the protein receptor the virus uses to gain access into cells. The compound appears to have anti-inflammatory effects and has previously been associated with a reduction in Alzheimer's symptoms.
A new study reports people with depression are 2.2 times more likely to endorse misinformation about the COVID-19 vaccine, and 2.7 times more likely to be vaccine-resistant. Additionally, rates of depression are three times higher than before the pandemic began.
A novel deep convolutional neural network AI algorithm can detect COVID-19 within minutes with 98% accuracy.
Patients who experienced cognitive impairments, or brain fog, following COVID-19 infection had abnormalities in their cerebrospinal fluid. Researchers say the overstimulation of the immune system as a result of COVID may be the cause of cognitive deficits.
At six months of age, babies born during the first year of the COVID-19 pandemic scored lower on developmental screening tests for social and motor skills than children born before the pandemic.
Researchers discuss how two years of living with the COVID-19 pandemic has impacted the types of New Year's resolutions people are likely to make for 2022.
Carriers of the Alzheimer's associated APOE4 gene have more than double the risk of developing severe COVID-19, a new study reports. Additionally, more microscopic hemorrhages were found in the brains of APOE4 carriers who contracted coronavirus. Researchers report those with the APOE4 gene also are more susceptible to developing long-term symptoms following COVID infection, including an increased risk of mental fatigue.
The COVID causing SARS-CoV-2 protein interacts with alpha-synuclein, speeding up the formation of amyloid plaques, a new study reports.
Researchers say the COVID pandemic has had an impact on people's cognitive abilities and risk perception.
Researchers examine how neuroimmune interactions promote brain plasticity and shed new light on how neuroimmune activity may have implications for a range of disorders, including neurological changes experienced by COVID-19 survivors.
A comparison of medical records reveals people who took SSRI antidepressants, specifically fluoxetine (Prozac), were less likely to die of COVID-19 than a matched control group. The findings add to a growing body of evidence that SSRIs may have beneficial effects against the worst symptoms of coronavirus.
COVID-19 infections in families widened the prosocial gap almost three-fold between people with higher socioeconomic status and those from backgrounds of lower socioeconomic status.